{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:49:06Z","timestamp":1793148546241,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T00:00:00Z","timestamp":1696464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["100308\/Z\/12\/Z"],"award-info":[{"award-number":["100308\/Z\/12\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_UU_12010\/3"],"award-info":[{"award-number":["MC_UU_12010\/3"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001275","name":"Oak Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001275","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.ebiom.2023.104840","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T19:04:18Z","timestamp":1697655858000},"page":"104840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors"],"prefix":"10.1016","volume":"97","author":[{"given":"Lise Torp","family":"Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrine E.","family":"Attfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2883-3226","authenticated-orcid":false,"given":"Lars","family":"Fugger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6589","key":"10.1016\/j.ebiom.2023.104840_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1126\/science.abn8933","article-title":"Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation","volume":"376","author":"Glassman","year":"2022","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104840_bib2","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nsmb.2807","article-title":"Structural basis of recognition of interferon-alpha receptor by tyrosine kinase 2","volume":"21","author":"Wallweber","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104840_bib3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1097-2765(01)00398-7","article-title":"Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases","volume":"8","author":"Zhou","year":"2001","journal-title":"Mol Cell"},{"issue":"22","key":"10.1016\/j.ebiom.2023.104840_bib4","doi-asserted-by":"crossref","first-page":"8025","DOI":"10.1073\/pnas.1401180111","article-title":"Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition","volume":"111","author":"Lupardus","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104840_bib5","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nsmb.2849","article-title":"Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinase","volume":"21","author":"Shan","year":"2014","journal-title":"Nat Struct Mol Biol"},{"issue":"49","key":"10.1016\/j.ebiom.2023.104840_bib6","doi-asserted-by":"crossref","first-page":"47954","DOI":"10.1074\/jbc.M205156200","article-title":"The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction","volume":"277","author":"Saharinen","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"5237","key":"10.1016\/j.ebiom.2023.104840_bib7","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1126\/science.270.5237.797","article-title":"Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development","volume":"270","author":"Russell","year":"1995","journal-title":"Science"},{"issue":"6544","key":"10.1016\/j.ebiom.2023.104840_bib8","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/377065a0","article-title":"Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2023.104840_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: impact on human disease\u00a0and therapeutic intervention","volume":"66","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"issue":"17","key":"10.1016\/j.ebiom.2023.104840_bib10","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A\u00a0gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"363","key":"10.1016\/j.ebiom.2023.104840_bib11","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag1974","article-title":"Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity","volume":"8","author":"Dendrou","year":"2016","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13045-021-01214-y","article-title":"STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer","volume":"14","author":"Awasthi","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104840_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1093\/emboj\/cdg038","article-title":"The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression","volume":"22","author":"Ragimbeau","year":"2003","journal-title":"EMBO J"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/jcb.24647","article-title":"Eliminative signaling by Janus kinases: role in the downregulation of associated receptors","volume":"115","author":"Carbone","year":"2014","journal-title":"J\u00a0Cell Biochem"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104840_bib15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2023.104840_bib16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104840_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104840_bib18","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.4049\/jimmunol.181.3.2071","article-title":"Tyk2-signaling plays an important role in host defense against Escherichia coli through IL-23-induced IL-17 production by gammadelta T cells","volume":"181","author":"Nakamura","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104840_bib19","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1172\/JCI200422315","article-title":"TYK2 is a key regulator of the surveillance of B lymphoid tumors","volume":"114","author":"Stoiber","year":"2004","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104840_bib20","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/intimm\/dxr057","article-title":"Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice","volume":"23","author":"Ishizaki","year":"2011","journal-title":"Int Immunol"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104840_bib21","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1084\/jem.20140280","article-title":"Human TYK2 deficiency: mycobacterial and viral infections without hyper-IgE syndrome","volume":"212","author":"Kreins","year":"2015","journal-title":"J\u00a0Exp Med"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104840_bib22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104840_bib23","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1002\/eji.201646519","article-title":"Tyrosine kinase 2 is not limiting human antiviral type III interferon responses","volume":"46","author":"Fuchs","year":"2016","journal-title":"Eur J Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib24","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s10875-019-00713-5","article-title":"A\u00a0new patient with inherited TYK2 deficiency","volume":"40","author":"Sarrafzadeh","year":"2020","journal-title":"J\u00a0Clin Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/pai.13671","article-title":"Novel mutations of TYK2 leading to divergent clinical phenotypes","volume":"33","author":"Lv","year":"2022","journal-title":"Pediatr Allergy Immunol"},{"issue":"8","key":"10.1016\/j.ebiom.2023.104840_bib26","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220131","article-title":"Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia","volume":"219","author":"Zhang","year":"2022","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104840_bib27","doi-asserted-by":"crossref","DOI":"10.1590\/1678-4685-gmb-2020-0425","article-title":"Association of TYK2 polymorphisms with autoimmune diseases: a comprehensive and updated systematic review with meta-analysis","volume":"44","author":"Pellenz","year":"2021","journal-title":"Genet Mol Biol"},{"issue":"30","key":"10.1016\/j.ebiom.2023.104840_bib28","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau8714","article-title":"Tuberculosis and impaired IL-23-dependent IFN-gamma immunity in humans homozygous for a common TYK2 missense variant","volume":"3","author":"Boisson-Dupuis","year":"2018","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib29","doi-asserted-by":"crossref","first-page":"7043","DOI":"10.1038\/s41598-018-25282-2","article-title":"The psoriasis-protective TYK2 I684S variant impairs IL-12 stimulated pSTAT4 response in skin-homing CD4+ and CD8+ memory T-cells","volume":"8","author":"Enerback","year":"2018","journal-title":"Sci Rep"},{"issue":"9","key":"10.1016\/j.ebiom.2023.104840_bib30","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1182\/blood-2007-09-113027","article-title":"Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia","volume":"111","author":"Tomasson","year":"2008","journal-title":"Blood"},{"issue":"Pt 3","key":"10.1016\/j.ebiom.2023.104840_bib31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/brain\/awr010","article-title":"Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility","volume":"134","author":"Couturier","year":"2011","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ebiom.2023.104840_bib32","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.4049\/jimmunol.1203118","article-title":"Two rare disease-associated Tyk2 variants are catalytically impaired but signaling competent","volume":"190","author":"Li","year":"2013","journal-title":"J\u00a0Immunol"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104840_bib33","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/ijc.34180","article-title":"Association of germline TYK2 variation with lung cancer and non-Hodgkin lymphoma risk","volume":"151","author":"Yarmolinsky","year":"2022","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ebiom.2023.104840_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104488","article-title":"Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases","volume":"89","author":"Yuan","year":"2023","journal-title":"EBioMedicine"},{"issue":"17","key":"10.1016\/j.ebiom.2023.104840_bib35","doi-asserted-by":"crossref","first-page":"i781","DOI":"10.1093\/bioinformatics\/bty556","article-title":"Insights on the alteration of functionality of a tyrosine kinase 2 variant: a molecular dynamics study","volume":"34","author":"Lesgidou","year":"2018","journal-title":"Bioinformatics"},{"issue":"21","key":"10.1016\/j.ebiom.2023.104840_bib36","doi-asserted-by":"crossref","first-page":"10430","DOI":"10.1073\/pnas.1903561116","article-title":"Homozygosity for TYK2 P1104A underlies tuberculosis in about 1% of patients in a cohort of European ancestry","volume":"116","author":"Kerner","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104840_bib37","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220094","article-title":"Impaired IL-23-dependent induction of IFN-\u03b3 underlies mycobacterial disease in patients with inherited TYK2 deficiency","volume":"219","author":"Ogishi","year":"2022","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104840_bib38","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ajhg.2021.02.009","article-title":"Human ancient DNA analyses reveal the high burden of tuberculosis in Europeans over the last 2,000 years","volume":"108","author":"Kerner","year":"2021","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ebiom.2023.104840_bib39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3389\/fimmu.2019.00044","article-title":"The TYK2-P1104A autoimmune protective variant limits coordinate signals required to generate specialized T cell subsets","volume":"10","author":"Gorman","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib40","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1038\/s41598-018-25260-8","article-title":"Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia","volume":"8","author":"Nemoto","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib41","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/genes14010029","article-title":"Polymorphisms in ACE1, TMPRSS2, IFIH1, IFNAR2, and TYK2 genes are associated with worse clinical outcomes in COVID-19","volume":"14","author":"Dieter","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.ebiom.2023.104840_bib42","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.cyto.2015.10.015","article-title":"Tyrosine kinase 2 - surveillant of tumours and bona fide oncogene","volume":"89","author":"Leitner","year":"2017","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3390\/cancers12010150","article-title":"TYK2 in tumor immunosurveillance","volume":"12","author":"Karjalainen","year":"2020","journal-title":"Cancers"},{"issue":"35","key":"10.1016\/j.ebiom.2023.104840_bib44","doi-asserted-by":"crossref","first-page":"9852","DOI":"10.1073\/pnas.1610253113","article-title":"Network pharmacology of JAK inhibitors","volume":"113","author":"Moodley","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104840_bib45","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s40265-020-01349-1","article-title":"Selectivity of Janus kinase inhibitors in rheumatoid arthritis and other immune-mediated inflammatory diseases: is expectation the root of all headache?","volume":"80","author":"Harigai","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104840_bib46","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1093\/rheumatology\/kez002","article-title":"Clinical significance of Janus kinase inhibitor selectivity","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104840_bib47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","article-title":"JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib","volume":"80","author":"Traves","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104840_bib48","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41589-022-01098-0","article-title":"Selective inhibitors of JAK1 targeting an isoform-restricted allosteric cysteine","volume":"18","author":"Kavanagh","year":"2022","journal-title":"Nat Chem Biol"},{"issue":"33","key":"10.1016\/j.ebiom.2023.104840_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo4363","article-title":"A\u00a0highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing gammac cytokine-related JAK-STAT signal","volume":"8","author":"Chen","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.ebiom.2023.104840_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103057","article-title":"Can rheumatologists stop causing demyelinating disease?","volume":"53","author":"Baker","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ebiom.2023.104840_bib51","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejphar.2015.06.060","article-title":"Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions","volume":"764","author":"Fukuyama","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104840_bib52","first-page":"1880","article-title":"CNS penetration of potential anti-COVID-19 drugs","volume":"267","author":"Richardson","year":"2020","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104840_bib53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1615\/CritRevImmunol.2016015517","article-title":"Opportunities for translation from the bench: therapeutic intervention of the JAK\/STAT pathway in neuroinflammatory diseases","volume":"35","author":"Liu","year":"2015","journal-title":"Crit Rev Immunol"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104840_bib54","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib55","doi-asserted-by":"crossref","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","article-title":"Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database","volume":"12","author":"Hoisnard","year":"2022","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104840_bib56","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/intimm\/dxu102","article-title":"Anti-TNF therapy: past, present and future","volume":"27","author":"Monaco","year":"2015","journal-title":"Int Immunol"},{"issue":"9865","key":"10.1016\/j.ebiom.2023.104840_bib58","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"10139","key":"10.1016\/j.ebiom.2023.104840_bib59","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib60","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13063-017-1870-2","article-title":"Why clinical trial outcomes fail to translate into benefits for patients","volume":"18","author":"Heneghan","year":"2017","journal-title":"Trials"},{"issue":"18","key":"10.1016\/j.ebiom.2023.104840_bib61","first-page":"1768","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. reply","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2023.104840_bib62","series-title":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions","year":"2021"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40744-022-00505-1","article-title":"Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases","volume":"10","author":"Salinas","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib64","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","article-title":"Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance","volume":"82","author":"Charles-Schoeman","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ebiom.2023.104840_bib65","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1093\/ibd\/izab112","article-title":"Effectiveness and safety of combining tofacitinib with a biologic in patients with refractory inflammatory bowel diseases","volume":"27","author":"Alayo","year":"2021","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.ebiom.2023.104840_bib66","article-title":"Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: a systematic review and meta-analysis","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104840_bib67","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1136\/annrheumdis-2020-218412","article-title":"Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis","volume":"80","author":"Fleischmann","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/rheumatology\/keac285","article-title":"Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy","volume":"62","author":"Amstad","year":"2022","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"issue":"45","key":"10.1016\/j.ebiom.2023.104840_bib70","doi-asserted-by":"crossref","first-page":"27261","DOI":"10.1074\/jbc.M115.672048","article-title":"Structural and functional characterization of the JH2 pseudokinase domain of JAK family tyrosine kinase 2 (TYK2)","volume":"290","author":"Min","year":"2015","journal-title":"J\u00a0Biol Chem"},{"issue":"17","key":"10.1016\/j.ebiom.2023.104840_bib71","doi-asserted-by":"crossref","first-page":"11061","DOI":"10.1074\/jbc.M114.619502","article-title":"Tyrosine kinase 2-mediated signal transduction in T lymphocytes is blocked by pharmacological stabilization of its pseudokinase domain","volume":"290","author":"Tokarski","year":"2015","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104840_bib72","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1039\/C6MD00560H","article-title":"Identification of imidazo[1,2-b]pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling","volume":"8","author":"Moslin","year":"2017","journal-title":"Medchemcomm"},{"issue":"502","key":"10.1016\/j.ebiom.2023.104840_bib73","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.ebiom.2023.104840_bib74","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1021\/acsmedchemlett.9b00035","article-title":"Identification of Imidazo[1,2-b]pyridazine derivatives as potent, selective, and orally active Tyk2 JH2 inhibitors","volume":"10","author":"Liu","year":"2019","journal-title":"ACS Med Chem Lett"},{"issue":"20","key":"10.1016\/j.ebiom.2023.104840_bib75","doi-asserted-by":"crossref","first-page":"8953","DOI":"10.1021\/acs.jmedchem.9b00443","article-title":"Identification of N-methyl nicotinamide and N-methyl pyridazine-3-carboxamide pseudokinase domain ligands as highly selective allosteric inhibitors of tyrosine kinase 2 (TYK2)","volume":"62","author":"Moslin","year":"2019","journal-title":"J\u00a0Med Chem"},{"issue":"20","key":"10.1016\/j.ebiom.2023.104840_bib76","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J\u00a0Med Chem"},{"issue":"14","key":"10.1016\/j.ebiom.2023.104840_bib77","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.ebiom.2023.104840_bib79","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/annrheumdis-2022-eular.2445","article-title":"POS1046 deucravacitinib long-term efficacy and safety in plaque psoriasis: 2-year results from the phase 3 POETYK PSO program","volume":"81","author":"Warren","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104840_bib80","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.ebiom.2023.104840_bib81","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1007\/s00125-016-4021-5","article-title":"JAK inhibition in the treatment of diabetic kidney disease","volume":"59","author":"Brosius","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.ebiom.2023.104840_bib82","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.881705","article-title":"Perspectives of JAK Inhibitors for large vessel vasculitis","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104840_bib83","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15437","article-title":"Janus kinase inhibitors for treatment of morphea and systemic sclerosis: a literature review","volume":"35","author":"McGaugh","year":"2022","journal-title":"Dermatol Ther"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104840_bib84","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ebiom.2023.104840_bib85","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v103.5346","article-title":"Itch and Janus kinase inhibitors","volume":"103","author":"Han","year":"2023","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib86","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1038\/s41467-022-32754-7","article-title":"Selective suppression of melanoma lacking IFN-gamma pathway by JAK inhibition depends on T cells and host TNF signaling","volume":"13","author":"Shen","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2023.104840_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119395","article-title":"Ruxolitinib attenuates experimental autoimmune encephalomyelitis (EAE) development as animal models of multiple sclerosis (MS)","volume":"276","author":"Hosseini","year":"2021","journal-title":"Life Sci"},{"key":"10.1016\/j.ebiom.2023.104840_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.650708","article-title":"Baricitinib ameliorates experimental autoimmune encephalomyelitis by modulating the Janus kinase\/signal transducer and activator of transcription signaling pathway","volume":"12","author":"Dang","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ebiom.2023.104840_bib89","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bbrc.2011.12.156","article-title":"Low dose CP-690,550 (tofacitinib), a pan-JAK inhibitor, accelerates the onset of experimental autoimmune encephalomyelitis by potentiating Th17 differentiation","volume":"418","author":"Yoshida","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.ebiom.2023.104840_bib90","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/epi.16848","article-title":"Tofacitinib treatment for refractory autoimmune encephalitis","volume":"62","author":"Jang","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebiom.2023.104840_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102568","article-title":"CNS demyelination during tofacitinib therapy: first report","volume":"46","author":"Massoud","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.ebiom.2023.104840_bib92","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15477","article-title":"New developing multiple sclerosis in a patient using tofacitinib due to alopesia areata","volume":"35","author":"Ercoban","year":"2022","journal-title":"Dermatol Ther"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104840_bib93","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.immuni.2022.10.016","article-title":"Emerging roles of innate and adaptive immunity in Alzheimer's disease","volume":"55","author":"Chen","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.ebiom.2023.104840_bib94","first-page":"1","article-title":"Cognitive improving actions of tofacitinib in a mouse model of Alzheimer disease involving TNF-alpha, IL-6, PI3K-Akt and GSK-3beta signalling pathway","author":"Sui","year":"2022","journal-title":"Int J Neurosci"},{"issue":"1","key":"10.1016\/j.ebiom.2023.104840_bib95","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41467-021-21330-0","article-title":"Machine learning identifies candidates for drug repurposing in Alzheimer's disease","volume":"12","author":"Rodriguez","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2023.104840_bib96","article-title":"Novel small molecule tyrosine kinase 2 pseudokinase ligands block cytokine-induced TYK2-mediated signaling pathways","volume":"13","author":"Zhou","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.ebiom.2023.104840_bib97","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","article-title":"Trends in clinical success rates and therapeutic focus","volume":"18","author":"Dowden","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"12","key":"10.1016\/j.ebiom.2023.104840_bib98","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008489","article-title":"Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval","volume":"15","author":"King","year":"2019","journal-title":"PLoS Genet"},{"issue":"7488","key":"10.1016\/j.ebiom.2023.104840_bib99","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature12873","article-title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery","volume":"506","author":"Okada","year":"2014","journal-title":"Nature"},{"issue":"7889","key":"10.1016\/j.ebiom.2023.104840_bib100","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41586-021-03767-x","article-title":"Mapping the human genetic architecture of COVID-19","volume":"600","year":"2021","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.ebiom.2023.104840_bib101","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3390\/cancers11111728","article-title":"TYK2: an upstream kinase of STATs in cancer","volume":"11","author":"Woss","year":"2019","journal-title":"Cancers"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423004061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396423004061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:28:15Z","timestamp":1762457295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396423004061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":101,"alternative-id":["S2352396423004061"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104840","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2023.104840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104840"}}